Cellectis S.A.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ALCLS.PA | ALLO | LYEL | HURA | SCLP.L | CHRS | |
|---|---|---|---|---|---|---|
| Market cap | 94.69M | 424.95M | 233.29M | 126.18M | 123.46M | 162.23M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.6 | -2.0 | -1.5 | -3.3 | -47.2 | -1.7 |
| Price/book | 1.9 | 1.0 | 1.0 | 6.9 | -4.9 | 2.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −66.61% | +9.92% | −48.64% | −6.50% | −5.55% | −38.92% |
| Today | −5.53% | −7.52% | +1.17% | −5.04% | +0.89% | +2.94% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ALCLS.PA news ›Multiple Myeloma Pipeline 2026: Who Is Leading the Race? Top Companies and Emerging Therapies to Watch by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics
Albany New York October 20 2026 As per DelveInsight s assessment globally Multiple Myeloma pipeline constitutes 75 key companies continuously working towards developing 80 Multiple Myeloma treatment therapies analysis of Clinical Trials…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS). Such investors are... NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims…
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Securities Fraud Investigation Into Cellectis S.A. (CLLS) GlobeNewswire 14, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R Cruz continues its investigation of Cellectis S.A (âCellectisâ or the âCompanyâ) (NASDAQ: CLLS) on…
Law firm probes Cellectis over stock drop after halting CAR-T therapy development
Pomerantz LLP is investigating Cellectis S.A. for potential securities fraud following the company's announcement to prioritize in vivo gene editing therapies and discontinue CAR-T cell therapies. This decision caused Cellectis's ADR price…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketbeat.com3
-
openpr.com2
-
globenewswire.com1
-
pluang.com1
-
prnewswire.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.